{"groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"FG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"FG001","title":"Everolimus"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}],"type":"Request to Discontinue Study Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Poor/Non-Compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"No Longer Meets Study Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"participant requested to be treated a local facility"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"410"},{"groupId":"FG001","numSubjects":"411"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"406"},{"groupId":"FG001","numSubjects":"397"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Randomized (Pre-treatment)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"316"},{"groupId":"FG001","numSubjects":"293"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"53"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"}],"type":"Adverse Event Unrelated to Study Drug"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"21"}],"type":"Request to Discontinue Study Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Maximal Clinical Benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"Administrative Reason by Sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"406"},{"groupId":"FG001","numSubjects":"397"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"406"},{"groupId":"FG001","numSubjects":"397"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"}],"preAssignmentDetails":"803 Participants Treated"}